Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Abstract Objectives B cell depletion by rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). However, peripheral B cell phenotypes and the selection criteria for RTX therapy in AAV remain unclear. Methods Phenotypic characterizati...

Full description

Bibliographic Details
Main Authors: Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Yuichi Ishikawa, Maiko Yoshikawa, Kei Sakata, Shigeru Iwata, Ippei Miyagawa, Kazuhisa Nakano, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Arthritis Research & Therapy
Subjects:
ANCA-associated vasculitis
B cell
Rituximab
Online Access:http://link.springer.com/article/10.1186/s13075-020-02215-x

Internet

http://link.springer.com/article/10.1186/s13075-020-02215-x

Similar Items